Frontlight ResearchEarly access
Taking peoplePhase 3
Keverprazan-Minocycline Dual Therapy of Different Durations Versus Bismuth Quadruple Therapy for Helicobacter Pylori Eradication.
Key facts
- Who runs it
- Nanjing First Hospital, Nanjing Medical University
- Where
- China1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Recruiting
- Phase
- Phase 3
- People taking part
- 612 people, planned
- Started
- 15 Jul 2026
- Expected to end
- 30 Dec 2027
- Type of study
- Interventional, 3 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- Minocycline
- Keverprazan
- Amoxicillin
- Colloidal Bismuth Pectin
- Record updated
- 5 November 2026
Who can take part
- Age
- 18 years to 65 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 14 criteriaShow less
Who can take part
- Age 18-65 years
- Positive H. pylori status confirmed by 13C-urea breath test and no prior history of eradication therapy
- Voluntary participation and provision of written informed consent
Who cannot take part
- Prior history of H. pylori eradication treatment
- Use of antibiotics or bismuth agents within 4 weeks before treatment initiation, or use of proton pump inhibitors within 2 weeks
- Current use of corticosteroids, nonsteroidal anti-inflammatory drugs, or anticoagulants
- Concurrent use of specific medications: atazanavir or rilpivirine, tricyclic antidepressants, levodopa, acetaminophen, guaifenesin/dextromethorphan, monoamine oxidase inhibitors, tramadol, or similar agents
- Allergy to any study medication (e.g., minocycline, keverprazan, amoxicillin)
- Confirmed active peptic ulcer disease
- History of esophageal or gastric surgery
- Severe comorbidities, including hepatic, cardiovascular, pulmonary, or renal disease
- Gastric mucosa-associated lymphoid tissue lymphoma, malignant tumors, peptic ulcer disease, or bronchial asthma
- Pregnancy or lactation
- Alcohol abuse
The main criteria, as questions
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 65 years old?
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
This study aims to compare the efficacy and safety of keverprazan-minocycline dual therapy versus bismuth-based quadruple therapy for Helicobacter pylori eradication, focusing on eradication rates, patient adherence, and the incidence of adverse drug reactions.
The 3 groups in the trial
- 10-day dual therapyTreatment being tested
Treatment: Minocycline and Keverprazan
- 14-day dual therapyTreatment being tested
Treatment: Minocycline and Keverprazan
- 14-day quadruple therapyExisting treatment, for comparison
Treatment: Minocycline, Keverprazan, Amoxicillin, and Colloidal Bismuth Pectin
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Efficacy and Safety of Keverprazan-minocycline Dual Therapy With Different Treatment Durations Versus Bismuth-based Quadruple Therapy for Helicobacter Pylori Eradication: an Open-label, Multicenter, Randomized, Non-inferiority Trial.
- Criteria questions
- Built from NCT07904429, who can take part
- Record updated
- 5 November 2026